Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$147.82 USD
+3.69 (2.56%)
Updated Aug 8, 2024 01:40 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 221 - 240 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
With Ingrezza On Track for TD, Focus Shifts Back to Pediatric Data in Tourette?s; Raising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Proprietary Survey of 100 Physicians Points to Ingrezza Bullishness: Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Proprietary Physician Survey Frames Value of Opicapone Deal; Reit Buy and Raising PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Topline Miss in Adults Does Not Deter Our Long-Term Confidence in TS
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
We See the Opportunity for Several Near-Term Value Inflection; Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Notes from Management Meeting: An Update on the INGREZZA NDA, Commercial Activities and De-risking for Tourette
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Incremental Pipeline Updates; Thesis Intact: Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Our Thoughts on Potential Launch Dynamics for NBI-98854 and SD-809
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Spotlight on Tourette?s: Initiating with Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A